Supreme Court Issues Directions to Speed Up MACT Claims Amid Six-Year Average Pendency  ||  Supreme Court: Sex Selection Practices Continues Due to Preference For Male Children  ||  Supreme Court: Injury From a Fallen Tree is Not a Motor Accident for MACT Claims  ||  Madras HC: Recent Tamil Nadu Elections Reflect Voting Beyond Caste and Community Considerations  ||  Supreme Court: Children Should Not Undergo Psychological Tests in Custody Cases Unless Necessary  ||  Jharkhand HC: Lokayukta Cannot Delegate Core Adjudicatory Powers Even in Case Against Brother  ||  Ker HC: Complainant Can Invoke Presumptions After Proving Transaction, Cheque Execution Convincingly  ||  Supreme Court Cancels SARFAESI Auction Sale After 16 Years Due to a 5-Day Payment Delay  ||  Jhar HC Orders 2-Month Probe Deadline, DGP Monitoring to Overhaul Sexual Violence Response in State  ||  Delhi HC: Social Media Cannot Undermine Judiciary; Intermediaries Must Act Without Court Orders    

Finalization of Draft Rules on Sale of Drugs by E-Pharmacies- (Press Information Bureau) (25 Jun 2019)

MANU/PIBU/0667/2019

Law of Medicine

The Government has published draft rules vide G.S.R. 817 (E) dated 28th August 2018 for inviting public/stakeholder comments for amendment to the Drugs and Cosmetics Rules, 1945 for incorporating provisions relating to regulation of sale and distribution of drugs through e-pharmacy. A large number of suggestions/comments have been received from the stakeholders, which are being examined. At the same time, the matter is sub-judice before various Hon'ble High Courts in the country. Therefore, no timeline for finalization of the rules can be provided.

Under the Drugs & Cosmetics Act and Rules, sale of spurious drugs is a punishable offence and State Licensing Authorities are empowered to take action in this regard. Accordingly, the complaints as received, are referred to State Licensing Authorities for taking action as per the provisions of the Act and Rules.

Tags : DRAFT RULES   FINALIZATION   SALE OF DRUGS   E-PHARMACIES  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved